Biotech Company developing Novel Oral mRNA–Based vaccines and biotherapeutics
East Lansing, MI – Michigan Rise is pleased to formally introduce Esperovax, developer of the Egress RD™ Oral Biologics platform, to its growing portfolio.
The Plymouth, Michigan-based company has developed a novel, mRNA-based oral vaccine platform that will enable large-scale production and distribution of shelf-stable vaccines and biological therapeutics. Their platform enables the prevention and treatment of some of the world’s deadliest diseases, including COVID-19, at a fraction of the cost of current injection-based therapies.
“We are grateful to Michigan Rise for recognizing the importance of our work,” said David O’Hagan, Ph.D., Esperovax Founder, President, and CEO. “It will play a role in our ability to provide rapid, painless, and inexpensive biological medicines that make a significant impact on global health.”
Esperovax’s Egress RD™ Oral Biologics platform utilizes common baker’s yeast as a novel mRNA vaccine delivery technology. This technology means billions of doses could potentially be manufactured in less than a month. This oral vaccine will not require costly purification processes, cold storage, or delivery devices such as syringes. Each dose can be economically produced and self-administered via pill or edibles.
